{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:59:43Z","timestamp":1767135583270,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd007057.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T00:00:00Z","timestamp":1359590400000}}],"reference-count":19,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007057.pub3","type":"journal-article","created":{"date-parts":[[2013,1,29]],"date-time":"2013-01-29T08:31:44Z","timestamp":1359448304000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis"],"prefix":"10.1002","volume":"2013","author":[{"given":"Patricia M","family":"Fortin","sequence":"first","affiliation":[{"name":"University of British Columbia; Department of Anesthesiology, Pharmacology and Therapeutics; 2176 Health Sciences Mall Vancouver BC Canada V6T 1Z3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron M","family":"Tejani","sequence":"additional","affiliation":[{"name":"University of British Columbia; Therapeutics Initiative; 2176 Health Sciences Mall Vancouver BC Canada V6T 1Z3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Bassett","sequence":"additional","affiliation":[{"name":"University of British Columbia; Department of Anesthesiology, Pharmacology and Therapeutics; 2176 Health Sciences Mall Vancouver BC Canada V6T 1Z3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijaya M","family":"Musini","sequence":"additional","affiliation":[{"name":"University of British Columbia; Department of Anesthesiology, Pharmacology and Therapeutics; 2176 Health Sciences Mall Vancouver BC Canada V6T 1Z3"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,31]]},"reference":[{"key":"10.1002\/14651858.CD007057.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"Quarterly Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007057.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","article-title":"Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis","volume":"15","author":"Booth","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD007057.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/BOR.0b013e32831d28b3","article-title":"Advances in the use of biologic agents for the treatment of systemic vasculitis","volume":"21","author":"Chung","year":"2009","journal-title":"Current Opinion in Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD007057.pub3-BIB0004|cit4","first-page":"146","article-title":"Clinical features, prognosis, and response to treatment in polyarteritis","volume":"55","author":"Cohen","year":"1980","journal-title":"Mayo Clinic Proceedings"},{"issue":"10","key":"10.1002\/14651858.CD007057.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/ndt\/16.10.2018","article-title":"The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review","volume":"16","author":"Groot","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD007057.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Groot","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD007057.pub3-BIB0007|cit7","first-page":"1","article-title":"Update on the treatment of Wegener's granulomatosis.","volume":"48","author":"Esper","year":"1999","journal-title":"Bulletin on the Rheumatic Diseases."},{"issue":"1","key":"10.1002\/14651858.CD007057.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.bor.0000200369.24793.f5","article-title":"Advances in the therapy of Wegener's granulomatosis","volume":"18","author":"Hellmich","year":"2006","journal-title":"Current Opinion in Rheumatology"},{"issue":"7414","key":"10.1002\/14651858.CD007057.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD007057.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener's granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007057.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD007057.pub3-BIB0012|cit12","first-page":"671","article-title":"Birmingham Vasculitis Activity Score in systemic necrotizing vasculitis","volume":"87","author":"Luqmani","year":"1994","journal-title":"QJM"},{"issue":"12","key":"10.1002\/14651858.CD007057.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.7326\/0003-4819-123-12-199512150-00005","article-title":"The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis","volume":"123","author":"Rao","year":"1995","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007057.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J","article-title":"An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients","volume":"43","author":"Reinhold-Keller","year":"2000","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD007057.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/ard.59.3.161","article-title":"Systemic Vasculitis: epidemiology, classification, and environmental factors","volume":"59","author":"Scott","year":"2000","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD007057.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group","volume":"335","author":"Stegeman","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007057.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","author":"The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007057.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/ncprheum0139","article-title":"Therapeutics of Wegener's granulomatosis","volume":"2","author":"Wung","year":"2006","journal-title":"Nature Clinical Practice Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD007057.pub3-BIB0019|cit19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007057.pub2","article-title":"Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis","author":"Fortin","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD007057.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T19:05:28Z","timestamp":1740337528000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007057.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Vascular Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,31]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007057.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,31]]}}}